NCT07229768
Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 8 words
- Trial completed
- Primary completion date changed from estimate of Nov 30, 2026 to Oct 10, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
AE
Timeframe: From enrolment to 12 months after the first dose
Secondary (2)
Radiation Dosimetry
ORR
Arms and interventions
177Lu-CTR-FAPI Treatment ArmExperimental
Drugs: 177Lu-CTR-FAPI
Sites
1 site in 1 country
- Shanghai General HospitalShanghai, China